Hakeem Health has raised $1.65 million led by Merak Capital to scale HakeemDx its AI clinical decision support platform across GCC hospitals. The bilingual tool integrates with EMR and lab systems to give clinicians real-time evidence-based guidance at the point of care.
Saudi Arabia's healthcare system sees tens of millions of clinical interactions every year, and a significant portion of them involve a doctor making a time-sensitive decision with imperfect information. Missed diagnoses, delayed treatment, and medication errors are not abstract problems in the region. They are expensive, preventable, and increasingly the focus of health system reform under Vision 2030. Hakeem Health, a Riyadh-based healthtech company founded in 2022 by Bilal Adi and Mohammed Ayyad, has built its entire product thesis around that specific problem. The company has now closed a $1.65 million funding round led by Merak Capital with participation from Sanabil 500, capital that will go directly toward accelerating the institutional adoption of its clinical AI platform across GCC hospitals.
The product at the center of this raise is HakeemDx, a clinical decision support platform that integrates with hospital systems including electronic medical records and laboratory platforms to deliver real-time, evidence-based guidance to clinicians at the point of care. The bilingual Arabic and English interface is not a cosmetic feature. It is a functional necessity in health systems where a significant share of clinicians trained internationally and operate in English while their patients and administrative systems are Arabic-first. HakeemDx gives doctors relevant clinical intelligence at the moment they need it, drawing on the patient's actual data from connected EMR and lab systems rather than operating on generic inputs. That integration layer is what separates a clinically useful tool from a sophisticated reference database.
Adi has been direct about the mission behind the company. Helping clinicians make better decisions faster so patients receive better care is both the founding premise and the commercial proposition. What Hakeem Health is betting on is that health systems in the GCC are ready to move from pilot-stage AI curiosity to platform-level institutional adoption, and that HakeemDx is built for exactly that transition. The platform is already targeting hospitals, universities, and healthcare payers through a scalable SaaS model built around recurring institutional contracts rather than individual user subscriptions, which gives it a revenue architecture that aligns with how health systems actually procure and budget technology.
Merak Capital's decision to lead the round is worth examining beyond the check size. The firm manages over SAR 3 billion across ten funds spanning venture capital, private equity, credit financing, and special projects. It is not a sector-specific healthcare fund making a thematic bet. Its participation reflects a broader conviction that AI delivers measurable productivity improvements across industries, and that healthcare is among the highest-impact areas remaining. Abdulelah Alshareef, Principal of Venture Capital at Merak Capital, positioned the investment explicitly around clinical decision-making quality and patient outcome improvement, framing Hakeem as addressing one of the most consequential inefficiencies in institutional healthcare. Sanabil 500's participation alongside Merak adds further credibility at the early institutional stage.
The addressable market Hakeem Health is working from is substantial. Saudi Arabia, the UAE, and Egypt together operate more than 2,000 hospitals, and healthcare spending across the GCC continues to grow as governments invest in expanding capacity, improving quality standards, and meeting the chronic disease burden that conditions like diabetes and cardiovascular disease are placing on the region's health systems. Institutional adoption of clinical AI tools is still early in the GCC relative to what has been deployed in North American and European hospital networks, but the gap is narrowing quickly as JCI-accredited facilities and national health authorities apply increasing pressure on clinical quality metrics.
For the Saudi healthtech ecosystem specifically, Hakeem Health joins a growing cluster of early-stage companies addressing clinical infrastructure rather than consumer wellness, a shift that reflects a more mature phase of health technology investment in the Kingdom. The combination of Merak Capital's multi-strategy institutional backing and Sanabil 500's accelerator-linked network gives the company both financial runway and the commercial relationships needed to move from early hospital deployments toward the kind of system-level contracts that define a durable B2B healthcare business.
